Cypress Capital Group Boosts Stock Holdings in Pfizer Inc. $PFE

Cypress Capital Group grew its position in Pfizer Inc. (NYSE:PFE) by 851.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 114,220 shares of the biopharmaceutical company’s stock after acquiring an additional 102,210 shares during the quarter. Cypress Capital Group’s holdings in Pfizer were worth $2,910,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Fiduciary Alliance LLC raised its position in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after buying an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Pfizer during the third quarter worth $3,019,000. Vista Investment Partners LLC raised its position in Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares during the period. Generali Investments CEE investicni spolecnost a.s. lifted its stake in shares of Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Pfizer by 11.2% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock valued at $48,225,000 after purchasing an additional 190,946 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer agreed to pay up to $530M for a non‑exclusive license to Novavax’s Matrix‑M adjuvant to boost its vaccine pipeline — a near‑term product development catalyst that can lift vaccine margins and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix‑M Adjuvant Technology
• Positive Sentiment: Analysis framing Pfizer as a “high‑yield pharma at a turning point” highlights valuation appeal and potential upside if pipeline execution and buybacks/dividends continue — a positive narrative for income and value investors. Pfizer: A High‑Yield Pharma At A Turning Point
• Neutral Sentiment: Pre‑earnings coverage summarizes Wall Street’s Q4 and key metric estimates — useful for gauging upcoming guidance/beat‑miss risk ahead of Pfizer’s results. Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
• Neutral Sentiment: A primer on seven companies Pfizer owns provides background on asset mix and diversification — helpful for longer‑term fundamental analysis but less likely to move the stock immediately. 7 Companies Owned by Pfizer
• Negative Sentiment: Zacks Research reportedly downgraded Pfizer to a “strong sell,” which can pressure sentiment and trigger short‑term outflows even if the broader fundamentals remain intact. Zacks Downgrades Pfizer
• Negative Sentiment: The CMS named multiple Pfizer drugs for a round of Medicare price negotiations — a direct regulatory risk that could compress future pricing and revenue for affected medicines. CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks
• Negative Sentiment: Coverage shows Pfizer underperforming peers recently, indicating relative weakness that can weigh on multiple‑day momentum and investor sentiment. Pfizer Inc. stock underperforms Wednesday when compared to competitors
• Negative Sentiment: Reporting indicates Pfizer is reshaping its portfolio (ViiV exit) amid a White House drug‑pricing push — strategic but potentially revenue‑dilutive and signaling near‑term uncertainty around growth composition. Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal

Pfizer Stock Up 0.9%

Shares of Pfizer stock opened at $26.08 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a 50 day moving average of $25.49 and a 200 day moving average of $25.02. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $148.28 billion, a P/E ratio of 15.16 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Ratings Changes

Several analysts recently issued reports on PFE shares. Citigroup began coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Finally, Scotiabank began coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.